CGON Cg Oncology Inc.

  1. Stocks
  2. Healthcare
  3. NASDAQ: CGON

Price (delayed)

$73.36

Market cap

$6.5B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.69

Enterprise value

$6.49B

?
Relative Growth: Rel. Growth: 35
Relative Strength: Rel. Strength: 90
Relative Valuation: Rel. Valuation: 1
Relative Profitability: Rel. Profitability: 6
Highlights
CGON's revenue is up by 23% since the previous quarter
CGON's equity has surged by 54% year-on-year but it is down by 6% since the previous quarter
The gross margin has plunged by 185% YoY and by 70% from the previous quarter
The gross profit has dropped by 109% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: https://cgoncology.com
Peers: AMGN GILD VRTX REGN

Key stats

What are the main financial stats of CGON

CGON stock price

How has the Cg Oncology stock price performed over time
Intraday
-5.63%
1 week
-1.03%
1 month
-8.08%
1 year
99.89%
YTD
76.69%
QTD
3.25%

Financial performance

How have Cg Oncology's revenue and profit performed over time
Revenue
$6.23M
Gross profit
-$5.31M
Operating income
-$252.62M
Net income
-$224.38M
Gross margin
-85.2%
Net margin
-3,602.7%
The gross margin has plunged by 185% YoY and by 70% from the previous quarter
The gross profit has dropped by 109% since the previous quarter
Cg Oncology's operating margin has surged by 86% YoY and by 4.3% QoQ
Cg Oncology's net margin has surged by 85% YoY and by 2.2% QoQ

Price vs fundamentals

How does CGON's price correlate with its fundamentals

Growth

What is Cg Oncology's growth rate over time

Valuation

What is Cg Oncology stock price valuation
P/E
N/A
P/B
6.29
P/S
1,038.91
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1,042.36
CGON's EPS has plunged by 52% YoY and by 15% from the previous quarter
CGON's equity has surged by 54% year-on-year but it is down by 6% since the previous quarter
The price to book (P/B) is 31% higher than the last 4 quarters average of 5.1
CGON's revenue is up by 23% since the previous quarter

Efficiency

How efficient is Cg Oncology business performance
CGON's ROS has soared by 85% YoY and by 2.2% from the previous quarter
The ROE has declined by 30% year-on-year and by 8% since the previous quarter
The company's return on assets fell by 28% YoY and by 8% QoQ
Cg Oncology's return on invested capital has decreased by 17% YoY and by 7% QoQ

Dividends

What is CGON's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CGON.

Financial health

How did Cg Oncology financials performed over time
Cg Oncology's total liabilities has surged by 82% YoY and by 30% QoQ
Cg Oncology's total assets has soared by 55% YoY but it has decreased by 4.4% from the previous quarter
Cg Oncology's debt is 99% lower than its equity
CGON's equity has surged by 54% year-on-year but it is down by 6% since the previous quarter
Cg Oncology's debt has increased by 16% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.